5-氨基-1,2,4-噻二唑盐酸盐 | 152513-91-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-氨基-1,2,4-噻二唑盐酸盐
• 中文别名: 5-氨基-1,2,4三噻唑盐酸盐；1,2,4-噻二唑-5-胺盐酸盐
• 英文名称: 1,2,4-thiadiazol-5-amine hydrochloride
• 英文别名: 1,2,4-thiadiazol-5-amine;hydrochloride
• CAS: 152513-91-2
• 化学式: C₂H₃N₃S*ClH
• mdl: MFCD19441985
• 分子量: 137.593
• InChiKey: JCIIKRHCWVHVFF-UHFFFAOYSA-N

物化性质

• 熔点：
  166-169℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.19
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 2-8°C |

反应信息

• 作为反应物：
  描述：

  5-氨基-1,2,4-噻二唑盐酸盐 在 potassium carbonate 作用下， 以 水 、 乙酸乙酯 为溶剂， 以36.8 g的产率得到5-氨基-1,2,4-噻二唑
  参考文献：
  名称：

  Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes

  摘要：

  The discovery and selection of a highly potent and selective Na(V)1.7 inhibitor PF-06456384, designed specifically for intravenous infusion, is disclosed. Extensive in vitro pharmacology and ADME profiling followed by in vivo preclinical PK and efficacy model data are discussed. A proposed protein-ligand binding mode for this compound is also provided to rationalise the high levels of potency and selectivity over inhibition of related sodium channels. To further support the proposed binding mode, potent conjugates are described which illustrate the potential for development of chemical probes to enable further target evaluation. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.09.056
• 作为产物：
  描述：

  5-氨基-1,2,4-噻二唑 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 5-氨基-1,2,4-噻二唑盐酸盐
  参考文献：
  名称：

  HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS

  摘要：

  本发明涉及用作离子通道抑制剂的杂环衍生物。该发明还提供了包含本发明化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病的方法。

  公开号：

  US20090131440A1

文献信息

• Heterocyclic derivatives as modulators of ion channels
  申请人：Martinborough Esther

  公开号：US20080027067A1

  公开（公告）日：2008-01-31

  The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及用作离子通道抑制剂的杂环衍生物。该发明还提供了包括本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。
• Heterocyclylaminomethyloxazo-lidinones as antibacterials
  申请人：AstraZeneca AB

  公开号：US20030207899A1

  公开（公告）日：2003-11-06

  Compounds of formula (I) 1 , or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q3 and Q5; R 2 and R 3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): wherein Rc is, for example, R 13 CO—, R 13 SO 2 — or R 13 CS—; wherein R 13 is, for example, optionally substituted (1-10C)alkyl or R 14 C(O)O(1-6C)alkyl wherein R 14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  化合物的公式（I）1，或其药用盐，或其体内可水解酯，其中，例如，HET是一个含有2到4个异原子（N、O和S）的可选择取代的C-连接的5元杂环芳烃环；Q可以从Q3和Q5中选择；R2和R3独立地为氢或氟；T可以从一系列基团中选择，例如，一个N-连接的（完全不饱和的）5元杂环芳烃环系统或一个公式（TC5）的基团：其中Rc是，例如，R13CO—，R13SO2—或R13CS—；其中R13是，例如，可选择取代的（1-10C）烷基或R14C(O)O(1-6C)烷基，其中R14是可选择取代的（1-10C）烷基；作为抗菌剂是有用的；并描述了它们的制备方法和含有它们的药物组合物。
• Heterocyclylaminomethyloxazolidinones as antibacterials
  申请人：AstraZeneca AB

  公开号：US06734200B1

  公开（公告）日：2004-05-11

  Compounds of formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, wherein, for example, HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q1 and Q2: R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): wherein Rc is, for example, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1-10C)alkyl or R14C(O)O(1-6C)alkyl wherein R14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  公式（I）的化合物，或其药学上可接受的盐，或其体内可水解的酯，其中，例如，HET是一种可选择的取代的C-连接的5成员杂环芳基环，其中含有2至4个独立选择自N、O和S的杂原子；Q从Q1和Q2中选择，例如：R2和R3独立地为氢或氟；T从一系列基团中选择，例如，一种N-连接的（完全不饱和的）5成员杂环芳基环系统或公式（TC5）的基团：其中Rc是，例如，R13CO—、R13SO2—或R13CS—；其中R13是，例如，可选择的取代的（1-10C）烷基或R14C（O）O（1-6C）烷基，其中R14是可选择的取代的（1-10C）烷基；这些化合物对抗菌有用；并描述了制造它们的过程和含有它们的药物组合物。
• Pyrrolidinyl phenyl sulphonamides as modulators of ion channels
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US08163720B2

  公开（公告）日：2012-04-24

  The present invention relates to phenyl sulfonamides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including for example the treatment of pain.

  本发明涉及苯基磺酰胺，其作为离子通道抑制剂的用途。本发明还提供了包含本发明化合物的药学上可接受的组合物，并提供了使用这些组合物治疗各种疾病的方法，例如治疗疼痛。
• PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS
  申请人：Martinborough Esther

  公开号：US20110082117A1

  公开（公告）日：2011-04-07

  The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及杂环衍生物，可用作离子通道抑制剂。本发明还提供了包含本发明化合物的药学上可接受的组合物，并提供了使用这些组合物治疗各种疾病的方法。